Schroder Investment Management Group
RNAM

Schroder Investment Management Group’s Avidity Biosciences RNAM Stock Holding History

Schroder Investment Management Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-406,031
Closed -$17.3M – 1202
2025
Q3 		$17.3M Buy
406,031
+62,313
+18% +$2.52M 0.01% 562
2025
Q2 		$9.76M Buy
343,718
+234,715
+215% +$7M 0.01% 643
2025
Q1 		$3.44M Buy
109,003
+47,523
+77% +$1.48M ﹤0.01% 827
2024
Q4 		$1.79M Buy
61,480
+30,697
+100% +$1.28M ﹤0.01% 939
2024
Q3 		$1.3M Buy
+30,783
New +$1.34M ﹤0.01% 1005

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Schroder Investment Management Group's RNAM Position: Q4 2025 in Review

Schroder Investment Management Group sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 406,031 shares — an estimated $17.3M sold.

Schroder Investment Management Group first reported a position in RNAM in Q3 2024 and held it in 5 quarters. The position peaked at $17.3M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Schroder Investment Management Group reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 406,031 Avidity Biosciences shares in Q4 2025, an estimated $17.3M.
  • Schroder Investment Management Group first reported a position in Avidity Biosciences in Q3 2024 and held it in 5 quarters.
  • Schroder Investment Management Group's Avidity Biosciences position peaked at $17.3M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.